PALEKAR ROHAN — SEC Form 4 filings
SEC reporting owner CIK 1423327. 17 Form 4 filings on record with FilingPulse; latest filed 2026-02-24.
Transaction summary — filings shown
Covers all 17 filings on record, filed 2024-01-18 to 2026-02-24. Counts and totals are arithmetic on values as filed — descriptive data, not a recommendation.
- Open-market purchases (code P, non-derivative): 2 legs across 2 filings — 15,000 shares, $122,950 total (shares × price as filed).
- Open-market sales (code S, non-derivative): 2 legs across 2 filings — 57,195 shares, $623,326 total (shares × price as filed).
- Other reported legs (grants, option exercises, tax withholding, gifts, derivative-security transactions, …): 29.
- Largest priced transaction: sale of 52,718 shares @ $10.91 ($575,153) in 89bio, Inc., filed 2024-04-03.
By issuer — same filings
Open-market purchase/sale legs on non-derivative securities, grouped by issuer. Role is as filed on the newest filing for that issuer. Dollar totals cover priced legs only (shares × price as filed). Ordered by priced transaction value, largest first.
| Issuer | Role (as filed) | Filings | Purchases (P) | Sales (S) | Other legs |
|---|---|---|---|---|---|
| 89bio, Inc. (ETNB) | Chief Executive Officer, Director | 13 | 2 legs · 15,000 sh · $122,950 | 2 legs · 57,195 sh · $623,326 | 25 |
| Neurogene Inc. (NGNE) | Director | 4 | — | — | 4 |
Form 4 filings — PALEKAR ROHAN
| Filed | Form | Issuer | Reported transactions | Source |
|---|---|---|---|---|
| 2026-02-24 | 4 | Neurogene Inc. (NGNE) | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2025-10-30 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 125,000 @ $0 · Code (U): 934,273 · Disposition to issuer (D): 120,231 (derivative) @ $0 · Disposition to issuer (D): 132,242 (derivative) @ $0 · Disposition to issuer (D): 170,000 (derivative) @ $0 · Disposition to issuer (D): 203,750 (derivative) @ $0 · +4 more | EDGAR |
| 2025-08-05 | 4 | 89bio, Inc. (ETNB) | Tax withholding (F): 55,836 @ $9.16 | EDGAR |
| 2025-06-13 | 4 | Neurogene Inc. (NGNE) | Grant/award (A): 12,050 (derivative) @ $0 | EDGAR |
| 2025-02-19 | 4 | 89bio, Inc. (ETNB) | Tax withholding (F): 3,249 @ $10.57 | EDGAR |
| 2025-02-11 | 4 | 89bio, Inc. (ETNB) | Tax withholding (F): 8,946 @ $11.41 | EDGAR |
| 2025-02-04 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 212,000 @ $0 · Grant/award (A): 200,000 @ $0 · Tax withholding (F): 9,598 @ $9.60 · Grant/award (A): 848,000 (derivative) @ $0 | EDGAR |
| 2024-12-10 | 4 | 89bio, Inc. (ETNB) | Purchase (P): 5,000 @ $7.89 | EDGAR |
| 2024-11-25 | 4 | 89bio, Inc. (ETNB) | Purchase (P): 10,000 @ $8.35 | EDGAR |
| 2024-08-19 | 4 | 89bio, Inc. (ETNB) | Tax withholding (F): 4,601 @ $8.04 | EDGAR |
| 2024-06-17 | 4 | Neurogene Inc. (NGNE) | Grant/award (A): 7,700 (derivative) @ $0 | EDGAR |
| 2024-04-03 | 4 | 89bio, Inc. (ETNB) | Option exercise (M): 25,000 @ $1.93 · Sale (S): 52,718 @ $10.91 · Option exercise (M): 25,000 (derivative) @ $0 | EDGAR |
| 2024-02-28 | 4 | 89bio, Inc. (ETNB) | Sale (S): 4,477 @ $10.76 | EDGAR |
| 2024-02-23 | 4 | 89bio, Inc. (ETNB) | Tax withholding (F): 4,602 @ $9.74 | EDGAR |
| 2024-02-13 | 4 | 89bio, Inc. (ETNB) | Tax withholding (F): 12,670 @ $8.45 | EDGAR |
| 2024-02-05 | 4 | 89bio, Inc. (ETNB) | Grant/award (A): 150,000 @ $0 · Tax withholding (F): 5,068 @ $9.80 · Grant/award (A): 605,000 (derivative) @ $0 | EDGAR |
| 2024-01-18 | 4 | Neurogene Inc. (NGNE) | Grant/award (A): 15,400 (derivative) @ $0 | EDGAR |
FilingPulse's Form 4 archive currently extends back to 2024-01-11 and is expanding backward through EDGAR history — earlier filings by this insider may not be indexed yet. Names and roles are shown as filed.
Need this as JSON?
GET https://api.filingpulse.io/v1/insider-trades?owner_cik=1423327 returns every filing on this page — normalized, with footnotes and derivative legs — and webhooks push new filings to you in seconds. API docs →